Newsroom

Industry News

16 Mar

Youngevity Announces Major Event in Mexico

SAN DIEGO, CA–(Marketwired – Mar 16, 2017) – Youngevity International, Inc. ( OTCQX : YGYI ), a leading omni-direct lifestyle company, today announced its inaugural corporate event taking place in Mexico March 24 and 25th. Youngevity’s Mexico head office is located in Guadalajara and is overseen by Country Manager, Alicia...

Read more

14 Mar

OncoSec Announces First Technology Access Program Agreement with Inhibrx

SAN DIEGO, March 14, 2017  /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that they have entered into a Technology Access Program (TAP) agreement with Inhibrx, LP, a privately held biotherapeutic company. Under the agreement, Inhibrx will use OncoSec’s proprietary gene...

Read more

14 Mar

Aytu BioScience Announces Peer-Reviewed Publication of Fourth Clinical Study Demonstrating the Utility of MiOXSYS® in the Assessment of Male Infertility

ENGLEWOOD, Colo., March 14, 2017 /PRNewswire/ — Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the publication of a peer-reviewed journal article demonstrating the clinical utility of the Company’s MiOXSYS® System for assessing the level of...

Read more

10 Mar

Fibrocell Announces One-for-Three Reverse Stock Split

EXTON, Pa., March 10, 2017 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it will effect a one-for-three reverse stock split of its common stock at 5:00 pm ET today.  Beginning...

Read more

10 Mar

Moleculin to Present at the 29th Annual Roth Capital Conference

HOUSTON, TX–(Marketwired – March 10, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center,...

Read more

9 Mar

Check-Cap Reports Fourth Quarter and Fiscal Year 2016 Financial Results

ISFIYA, Israel, March 9, 2017 /PRNewswire/ — Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today provided a corporate update and announced its financial results for the fourth quarter...

Read more

9 Mar

CymaBay Therapeutics to Present at Two Investor Conferences in March

NEWARK, Calif., March 09, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced that management will provide a corporate overview at the 29th Annual ROTH Conference, being held March 12-15, 2017...

Read more

9 Mar

Fibrocell Reports 2016 Financial Results and Recent Operational Highlights

EXTON, Pa., March 09, 2017 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the year ended December 31, 2016 and recent operational highlights. Fibrocell will host a conference call...

Read more

Page 3 of 22212345...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address